Serum GFAP as a biomarker for disease severity in multiple sclerosis

Serum GFAP as a biomarker for disease severity in multiple sclerosis

While neurofilament light chain (NfL) measurement in serum is a well-established marker of neuroaxonal damage in multiple sclerosis (MS), data on astroglial markers in serum are missing. In our study, glial fibrillary acid protein (GFAP) and NfL were measured in cerebrospinal fluid (CSF) and serum o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Scientific reports 2018-10, Vol.8 (1), p.14798-7, Article 14798
Hauptverfasser: Abdelhak, A., Huss, A., Kassubek, J., Tumani, H., Otto, M.
Format: Artikel
Sprache:eng
Schlagworte:
692/617/375/1666
692/617/375/365
Autoimmune diseases
Cerebrospinal fluid
Expanded Disability Status Scale (EDSS)
GFAP Levels
Glial fibrillary acidic protein
Glial Fibrillary Acidic Protein (GFAP)
Humanities and Social Sciences
Lesions
Magnetic resonance imaging
multidisciplinary
Multiple sclerosis
Neurological diseases
Relapsing-remitting MS (RRMS)
Science
Science (multidisciplinary)
Serum GFAP
Serum levels
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:While neurofilament light chain (NfL) measurement in serum is a well-established marker of neuroaxonal damage in multiple sclerosis (MS), data on astroglial markers in serum are missing. In our study, glial fibrillary acid protein (GFAP) and NfL were measured in cerebrospinal fluid (CSF) and serum of MS patients and patients with other non-inflammatory neurological diseases (OND) using the Simoa technology. Clinical data like age, gender, expanded disability status scale (EDSS) and MRI findings were correlated to neurochemical markers. We included 80 MS patients: 42 relapsing-remitting MS (RRMS), 38 progressive MS (PMS), as well as 20 OND. Serum GFAP levels were higher in PMS compared to RRMS and OND (p 
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-018-33158-8